JMP Securities Maintains Macrogenics(MGNX.US) With Hold Rating
MacroGenics Downgraded to Market Perform by JMP, Price Target Removed
A Quick Look at Today's Ratings for Macrogenics(MGNX.US), With a Forecast Between $4 to $8
MacroGenics (MGNX) Was Downgraded to a Hold Rating at JMP Securities
MacroGenics' Strategic Moves and Promising Pipeline Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Treace Medical Concepts (TMCI), MacroGenics (MGNX) and Novo Nordisk (NVO)
Macrogenics Analyst Ratings
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
Balanced Hold Rating Reflects Cautious Optimism and Strategic Risks for MacroGenics
Barclays Maintains Macrogenics(MGNX.US) With Buy Rating, Maintains Target Price $8
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
BMO Capital Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $5
JMP Securities Maintains Macrogenics(MGNX.US) With Buy Rating, Maintains Target Price $8
MacroGenics (MGNX) Receives a Buy From JMP Securities
Macrogenics Analyst Ratings
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
Evercore ISI Sticks to Their Buy Rating for MacroGenics (MGNX)
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $6
Evercore Maintains Macrogenics(MGNX.US) With Buy Rating